Overview

Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of vildagliptin 50 mg bid in elderly patients with Type 2 Diabetes Mellitus (T2DM).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Vildagliptin